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Background: The emergence of the novel coronavirus disease 2019 (COVID-19) has
caused millions of deaths worldwide. There has been paucity of data for hospitalized
African patients suffering from COVID-19. This study aimed to identify factors associated
with in-hospital mortality in patients suffering from COVID-19 in Tanzania.
Methods: This was a single center, retrospective, observational cohort study in adult patients
hospitalized with confirmed COVID-19 infection. Demographics, clinical pattern, laboratory
and radiological investigations associated with increased odds of mortality were analyzed.
Results: Of the 157 patients, 107 (68.1%) patients survived and 50 (31.8%) died. Mortality
was highest in patients suffering with severe (26%) and critical (68%) forms of the disease.
The median age of the cohort was 52 years (IQR 42–61), majority of patients were male
(86%) and of African origin (46%), who presented with fever (69%), cough (62%) and
difficulty in breathing (43%). Factors that were associated with mortality among our cohort
were advanced age (OR 1.07, 95% CI 1.03–1.11), being overweight and obese (OR 9.44,
95% CI 2.71–41.0), suffering with severe form of the disease (OR 4.77, 95% CI 1.18–25.0)
and being admitted to the HDU and ICU (OR 6.68, 95% CI 2.06–24.6).
Conclusion: The overall in-hospital mortality was 31.8%. Older age, obesity, the severe
form of the disease and admission to the ICU and HDU were major risk factors associated
with in-hospital mortality.
Keywords: COVID-19, factors, hospital, mortality, Tanzania
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Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 first emerged in
Hubei Province, China in December 2019. Since then, not only has COVID-19
been considered a health emergency of international concern1 but it has also been
declared a global pandemic.1 As of 9th July, 2021, the World Health Organization
(WHO) officially confirmed over 185 million cases of COVID-19 globally with
4 million deaths. Tanzania reported its first case on 16th March 2020.2 Even
though most African countries have a fragile health system, the Case Fatality Rate
(CFR) for COVID-19 in Africa is surprisingly lower than the global trend.3 Low
testing rates, a younger population, humid temperatures and possibility of
a preexisting immunity are some of the postulated factors associated with this
difference.3
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Although the SARS-CoV-2 virus predominantly targets
the respiratory system,4 its associated mortality involves
multiple organ systems.4 An increasing understanding of
the disease over the course of the pandemic has led to reduc
tion in in-hospital mortality rates, especially in wellresourced and high-income countries.5–7 In contrast, inhospital mortality remains comparatively high in Africa.
This has been attributed to the burden of underlying comor
bidities and resource deficits.8 Reports globally have indi
cated that increasing age,9–11 comorbidities (cardiovascular
disease, diabetes)9,12,13 and obesity14,15 are all associated
with adverse outcomes. In addition, certain demographic
characteristics10–12,16 and laboratory parameters17–19 have
also been associated with the severe form of COVID-19
and increased mortality.
In Tanzania, the population characteristics skew
towards the younger age range and a lower life expectancy
compared to higher-income countries. Despite the alarm
ing growing numbers of non-communicable diseases
(NCD),20 communicable diseases such as human immuno
deficiency virus (HIV), tuberculosis, malaria and other
neglected infectious diseases are still highly prevalent in
the population. The objective of the present study was to
describe clinical features and identify risk factors asso
ciated with mortality among patients hospitalized with
COVID-19 in Tanzania.

Methodology
Study Design and Participants
This was a retrospective cohort study of adults aged 18
years and above admitted to the COVID-19 isolation unit
between 29th March and 31st July 2020. We enrolled
eligible patients that were hospitalized with confirmed
COVID-19 via a positive SARS-CoV-2 RT-PCR and had
a final outcome (either death or discharge). The criteria for
discharge was maintenance of oxygen saturation at rest or
above 94% on room air, respiratory rate less than 24
breaths/min and absence of fevers over a 24-hour period.

Study Location
The study was conducted at the COVID-19 isolation unit
of the Aga Khan Hospital, Dar es Salaam, Tanzania. The
Aga Khan Hospital, Dar es Salaam is the only Joint
Commission International (JCI) accredited hospital in the
country. The COVID-19 isolation unit is housed in
a building separate from other patients and comprises the
general isolation ward and the COVID-19 Critical Care
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Unit (CCU). The CCU is split into the intensive care unit
(ICU) and the high dependency unit (HDU). The general
isolation ward consisted of two separate wards (one for
suspect cases and one for confirmed positive PCR patients)
located on two separate floors with 25 beds each. The
COVID-19 CCU has an eight-bed ICU and twelve-bed
HDU. The suspect and confirmed isolation ward is over
seen by a clinical team that is composed of specialists
from the department of internal medicine, paediatrics, as
well as residents, medical officers, and interns. Both the
HDU and ICU are managed by a multidisciplinary team,
which includes a full-time critical care specialist, primary
physician, internal medicine resident, medical officer, phy
siotherapist and dietician. The ICU is able to provide both
invasive and non-invasive mechanical ventilation, invasive
hemodynamic monitoring, and inotropic support. The
HDU serves as a step-down unit for the ICU and houses
patients who are critically ill requiring high-flow oxygen.
Patients requiring hemodialysis are transferred to
a separate designated dialysis unit within the isolation
unit. The ICU and HDU have round-the-clock coverage
with an anesthesiologist and a team of medical officers
from various specialties such as internal medicine,
anesthesia, and emergency medicine. The nurse-to-patient
ratio for ICU and HDU was 1:1 and 1:4, respectively.

Data Collection
We obtained medical records and compiled data for adult
patients aged 18 years and above with laboratory confirmed
COVID-19 as tested by the National Public Health
Laboratory, between 29th March and 31st July 2020. The
admission register was used to identify patients; their files
both electronic and paper-based were retrieved from medical
records. Patient demographics, clinical and laboratory data as
well as radiological findings and outcomes were obtained.
Data were collected by research assistants who had experi
ence working in the COVID-19 isolation unit. Extracted data
were independently verified by the primary investigator for
accuracy and completeness. We categorized race into three
main categories: African, South Asians (Indians and
Pakistanis) and Chinese. The rest were grouped under
“Others”. Patients’ initial radiographs, done on admission
to the hospital, were classified broadly into four main groups:
local patchy shadowing, bilateral patchy shadowing, inter
stitial abnormalities and ground glass opacification. Patient’s
clinical status21 and Body Mass Index (BMI) were classified
according to WHO classification.22
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Laboratory Procedures and Treatment
Protocol
Nasal and oropharyngeal swab samples for patients admitted
were collected by trained laboratory technicians and placed
in sterile viral transport media tubes. These were delivered
to the National Public Health Laboratory (NPHL) strictly
following government and WHO protocols for collection,
storage and transport. At NHPL, the samples were tested for
SARS-CoV-2 using reverse transcription-polymerase chain
reaction (RT-PCR). Results were mailed back to the hospital
through a central and local public health body reporting
mechanism. A confirmed case of COVID-19 was defined
as positive on RT-PCR assay of nasal and oropharyngeal
swab specimens.
The standard institutional guideline for COVID-19
patients was divided into two: (i) general management
and (ii) COVID-19 specific therapy. General management
included the guidance on the use of empiric treatment
(intravenous (IV) Ceftriaxone 1000 mg twice daily or IV
Piperacillin-Tazobactam 4500 mg thrice daily) for bacter
ial co-infection, prevention and therapy of venous throm
boembolism for all hospitalized patients, the use of IV
paracetamol for fever, treatment of underlying conditions,
protocols for chest physiotherapy, nutritional guidance and
a note to avoid forms of medication given by nebulization
to prevent aerosolization of viral particles. At the time of
this study, the only COVID-19 specific therapy used was
daily systemic corticosteroids either intravenous
Dexamethasone 6 mg IV once daily or oral Prednisolone
0.5mg/kg/day in two divided doses, but this was limited to
those who required oxygen or who were critically ill. We
encouraged all oxygen-dependent hospitalized patients to
spend as much time as practical and safe in prone position.
For patients requiring oxygen supplementation, we fol
lowed recommendations from WHO which suggested
titrating oxygen to target peripheral oxygen saturation
(SpO2) of ≥94% with the lowest fraction of inspired oxy
gen (FiO2). The decision to intubate was multifactorial and
was dependent on clinical and gas exchange parameters.

Statistical Analysis
Demographic data were summarized using frequency
tables and percentages, while continuous and categorical
variables were presented as median (IQR) and n (%),
respectively. A chi-square test/Fisher's exact test was
used to identify the presence of a statistical significant
difference between survivors and non-survivors.
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Statistical significant difference was set at a p-value of
<0.05. To identify factors associated with mortality in
hospitalized COVID-19 disease, logistic regression
model was used. Variables significantly associated with
disease severity at 5% level of significance in the univari
ate analysis were considered in the multivariable model. In
the final model, adjusted odds ratio (OR), p-value and 95%
CI for OR were used to test significance and interpretation
of results. Variables with p-value ≤0.05 were considered as
major risk factors associated with mortality. All analyses
were performed using STATA software version 15
(College Station, TX).

Results
During the study period; 157 patients who tested positive
for SARS-CoV-2 were included in the analysis of the
study, out of which 107 (68.2%) survived, while 50
(31.8%) died. Table 1 shows general and clinical charac
teristics of the cohort and provides a comparison of survi
vors to non-survivors. The median age of the cohort was
52 years (IQR 42–61). The majority of the population
were male (86%) and of African origin (46%). More
than one comorbid condition per critically ill patient was
recorded when present. The most common comorbid con
dition amongst our cohort was diabetes mellitus (11%) and
hypertension (7.6%). Most notably two-thirds of the
cohort population was either overweight (30%) or obese
(37%). The overall median length of stay was 6 days (IQR
3–10). Higher percentage of mortality with statistical sig
nificance (P < 0.05) was noted amongst males (78%), aged
between 45 and 64 years (44%), those who were suffering
from both diabetes mellitus as well as hypertension (30%)
and those who were obese (62%).
Majority of our patients were symptomatic; the most
common symptoms on admission were fever (69%), cough
(62%) and difficulty in breathing (43%) as shown in
Table 2. Vitals on admission were evaluated; the overall
median respiratory and pulse rates were 24 breaths/min
(IQR 20–30) and 98 beats/min (IQR 85–110), respectively.
When survivors and non-survivors were compared,
a higher percentage of mortality with statistical signifi
cance (P < 0.05) was noted in those who presented with
difficulty in breathing (54%). Additionally, a higher
respiratory rate of 28 breaths/min (IQR 24–33) and pulse
rate of 104 beats/min (IQR 90–120) was noted amongst
non-survivors (P < 0.05). No statistically significant dif
ference was noted when systolic and diastolic blood
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Table 1 Demographic and Clinical Characteristics of Patients
Variable
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Age

157

Overall, N = 157a

Patient Outcome
Survivor, N = 107a

Non-Survivors, N = 50a

52 (42–61)

48 (37–57)

60 (49–69)

< 45
45–64

52 (33%)
71 (45%)

44 (41%)
49 (46%)

8 (16%)
22 (44%)

65–74

27 (17%)

11 (10%)

16 (32%)

>75

7 (4.5%)

3 (2.8%)

4 (8.0%)

22 (14%)
135 (86%)

11 (10%)
96 (90%)

11 (22%)
39 (78%)

72 (46%)

45 (42%)

27 (54%)

South Asians

53 (34%)

32 (30%)

21 (42%)

Chinese
Others

9 (5%)
23 (15%)

9 (8.4%)
21 (9.6%)

0 (0%)
2 (4.0%)

Sex

157

Female
Male
Race
African

Comorbids
None

p-valueb

<0.001

0.049

157

<0.001

157
62 (39%)

58 (54%)

4 (8.0%)

< 0.0001

DM

18 (11%)

15 (14%)

3 (6.0%)

0.1418

HTN
HIV

12 (7.6%)
4 (2.5%)

9 (8.4%)
1 (0.9%)

3 (6.0%)
3 (6.0%)

0.5963
0.0606

Asthma or COPD
DM & HTN

9 (5.7%)
29 (18%)

3 (2.8%)
14 (13%)

6 (12%)
15 (30%)

0.0209
0.0109

DM, HTN, and CKD

9 (5.7%)

6 (5.6%)

3 (6.0%)

0.9215

DM, HTN, and CAD
Others

4 (2.5%)
10 (6.4%)

0 (0%)
1 (0.9%)

4 (8.0%)
9 (18%)

0.0030
< 0.0001

44 (33%)

39 (45%)

5 (10%)

Overweight

40 (30%)

27 (31%)

13 (27%)

Obese

50 (37%)

20 (23%)

30 (62%)

6 (3-10)

6 (4-11)

3 (1-7)

BMI
Healthy weight

134

LOS (Days)
a

<0.001

<0.001

b

Notes: Median (IQR) or frequency (%) Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test.
Abbreviations: DM, diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease;
BMI, body mass index; LOS, length of stay; <, less than; >, more than.

pressures were compared amongst survivors and nonsurvivors.
More than half (67%) patients required oxygen supple
mentation on admission as seen in Table 3 either via nasal
prongs (16%), face mask (7.6%) or non-rebreather mask
(39%). Six patients (3.8%) were intubated at accident's and
emergency department prior to admission, of which five
did not make it to hospital discharge. Normal chest X-ray
on admission was only noted amongst 20 patients (15%),
with the majority having radiological features suggestive
of bilateral patchy shadowing (34%) or ground glass opa
cities (24%). The bulk of the admissions was patients
suffering from the severe (39%) and critical (29%) form
of the disease. When survivors and non-survivors were
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compared, higher mortality rates were noted in those
who required oxygen support via non-rebreather mask
(66%), suffering with critical illness (68%) and those
who required intensive care (40%).
Table 4, below illustrates initial laboratory parameters
of our study population and provides a comparison of
survivors to non-survivors. We observed a statistically sig
nificant difference (P < 0.05) in initial laboratory findings
between survivors and non-survivors. Non-survivors had
a significantly higher median leukocyte count 10.4×109/L
(IQR 6.3 −14.9), absolute neutrophil count 8.3×109/L
(IQR 5.0–13.9) and an elevated C-reactive protein (CRP)
207 mg/L (IQR 90–301). Likewise, higher levels of serum
Lactate Dehydrogenase (LDH) 504 IU/L (IQR 412–728),
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Table 2 Presenting Symptoms and Initial Vitals on Admission
Variable

N

Overall, N = 157a

p-valueb

Patient Outcome
Survivor, N = 107a

Non-Survivors, N = 50a

97 (62%)
108 (69%)

74 (69%)
75 (70%)

23 (46%)
33 (66%)

International Journal of General Medicine downloaded from https://www.dovepress.com/ by 197.248.65.33 on 05-Nov-2021
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Symptoms
Cough
Fever

157
157

0.005
0.61

Difficulty breathing

157

67 (43%)

40 (37%)

27 (54%)

0.050

Malaise
Headache

157
157

47 (29.9%)
17 (11%)

46 (43%)
17 (16%)

1 (2.0%)
0 (0%)

<0.001
0.003

Gastrointestinal symptoms

157

13 (8.3%)

8 (7.5%)

5 (10%)

0.76

Others

157

9 (5.7%)

4 (3.7%)

5 (10%)

0.14

157
157

24 (20–30)
126 (117–140)

23 (19–26)
128 (120–140)

28 (24–33)
123 (109–140)

<0.001
0.11

Diastolic blood pressure (mmHg)

157

80 (70–87)

80 (74–87)

78 (60–84)

0.073

SpO2 (%)
Heart rate (beats/min)

157
157

92 (88–96)
98 (85–110)

94 (90–96)
93 (84–105)

88 (78–93)
104 (90–120)

<0.001
<0.001

Vitals
Respiratory rate (breaths/min)
Systolic blood pressure (mmHg)

Notes: aMedian (IQR) or frequency (%), bWilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test.
Abbreviation: SpO2, oxygen saturation.

Table 3 Type of Initial Respiratory Support, Chest X-Ray Findings, Admitting Ward and Severity of the Disease on Admission
Variable

N

Overall, N = 157a

p-valueb

Patient Outcome
Survivor, N = 107a

Non-Survivors, N = 50a

52 (33%)

50 (47%)

2 (4.0%)

Nasal prongs

25 (16%)

22 (21%)

3 (6.0%)

Face mask
Non-rebreather mask

12 (7.6%)
62 (39%)

5 (4.7%)
29 (27%)

7 (14%)
33 (66%)

Intubated

6 (3.8%)

1 (0.9%)

5 (10%)

Normal

20 (15%)

19 (21%)

1 (2.2%)

Bilateral patchy shadowing
Ground glass opacities

46 (34%)
32 (24%)

26 (29%)
19 (21%)

20 (43%)
13 (28%)

Interstitial abnormalities

9 (6.7%)

5 (5.6%)

4 (8.7%)

Local patchy shadowing
Others

12 (8.9%)
16 (12%)

9 (10%)
11 (12%)

3 (6.5%)
5 (11%)

99 (63%)

85 (79%)

14 (28%)

HDU

29 (18%)

13 (12%)

16 (32%)

ICU

29 (18%)

9 (8.4%)

20 (40%)

51 (32%)

48 (45%)

3 (6.0%)

Severe

61 (39%)

48 (45%)

13 (26%)

Critical

45 (29%)

11 (10%)

34 (68%)

Initial support
No support

157

Chest x-ray

135

Admitted to
General ward

0.029

157

Severity
Moderate

a

<0.001

<0.001

157

<0.001

b

Notes: Median (IQR) or frequency (%), Fisher’s exact test; Pearson’s Chi-squared test.
Abbreviations: HDU, high dependency unit; ICU, intensive care unit.
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Table 4 Laboratory Parameters on Admission
Variable

N
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WBC (109/L)

p-valueb

Patient Outcome
Survivor, N = 107a

Non-Survivors, N = 50a

7.9 (5.7–10.8)

7.2 (5.4–9.4)

10.4 (6.3–14.9)

<4

8 (5.2%)

6 (5.8%)

2 (4.0%)

4–10

98 (64%)

77 (74%)

21 (42%)

> 10

48 (31%)

21 (20%)

27 (54%)

ANC (109/L)

154

Overall, N = 157a

5.9 (3.8–9.2)

5.4 (3.5–8.0)

8.3 (5.0–13.9)

< 1.8

3 (1.9%)

3 (2.9%)

0 (0%)

1.8–6.3

81 (53%)

62 (60%)

19 (38%)

> 6.3

70 (45%)

39 (38%)

31 (62%)

ALC (109/L)

154

0.89 (0.65–1.45)

0.88 (0.65–1.37)

1.00 (0.67-1.63)

< 0.8

64 (42%)

44 (42%)

20 (40%)

0.8–1.0

20 (13%)

15 (14%)

5 (10%)

> 1.0

70 (45%)

45 (43%)

25 (50%)

CRP (mg/L)

154

134 (52–267)

109 (47–220)

207 (90–301)

< 50

37 (25%)

29 (28%)

8 (17%)

50–100

23 (15%)

18 (17%)

5 (10%)

100–200

37 (25%)

26 (25%)

11 (23%)

> 200

54 (36%)

30 (29%)

24 (50%)

LDH (IU/L)

151

446 (304–576)

392 (282–533)

504 (412–728)

≤ 225

16 (12%)

14 (15%)

2 (4.3%)

> 225

123 (88%)

79 (85%)

44 (96%)

D-dimer (mg/L)

139

0.68 (0.39–1.93)

0.58 (0.35–1.34)

1.44 (0.58–5.74)

< 0.5

46 (34%)

39 (41%)

7 (18%)

0.5–1.0

32 (24%)

21 (22%)

11 (28%)

> 1.0

56 (42%)

34 (36%)

22 (55%)

928 (525–1843)

960 (525–1905)

829 (563–1573)

39

21

18

Ferritin (µg/L)

134

118

Unknown
< 250

19 (16%)

14 (16%)

5 (16%)

250–500

10 (8.5%)

7 (8.1%)

3 (9.7%)

> 500

88 (75%)

65 (76%)

23 (74%)

INR

1.15 (1.10–1.34)

1.13 (1.07–1.27)

1.25 (1.15–1.64)

0–1

72

4 (5.6%)

3 (6.5%)

1 (3.8%)

1.0–1.5

56 (78%)

38 (83%)

18 (69%)

> 1.5

12 (17%)

5 (11%)

7 (27%)

BUN (mmol/L)

5.9 (3.9–9.9)

5.0 (3.3–7.6)

8.2 (4.8–12.4)

≤ 9.5

118

87 (74%)

60 (83%)

27 (59%)

> 9.5

31 (26%)

12 (17%)

19 (41%)

85 (72–114)

82 (71–101)

95 (76–134)

≤ 104

88 (69%)

63 (79%)

25 (53%)

> 104

39 (31%)

17 (21%)

22 (47%)

Creatinine (μmol/L)

AST (IU/L)

127

49 (29–83)

38 (25–66)

64 (42–99)

≤ 40

34 (42%)

27 (54%)

7 (23%)

> 40

47 (58%)

23 (46%)

24 (77%)

35 (22–65)

40 (22–67)

33 (22–54)

46 (56%)

25 (50%)

21 (66%)

36 (44%)

25 (50%)

11 (34%)

ALT (IU/L)

81

82

≤ 41
> 41
a

<0.001

<0.001

0.47

0.004

0.002

<0.001

0.79

0.007

<0.001

0.040

0.007

0.57

b

Notes: Median (IQR) or frequency (%) Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test.
Abbreviations: ANC, absolute neutrophil count; ALC, absolute lymphocyte count; CRP, C-reactive protein; LDH, lactate dehydrogenase; INR, international normalized
ratio; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; <, less than; >, more than.
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D-dimer 1.44 mg/L (IQR 0.58–5.74) and deranged
International Normalized Ratio (INR) 1.25 (IQR 1.15–
1.64) were noted amongst the non-survivors (P < 0.05).
Absolute lymphocyte counts and ferritin levels did not
reveal any statistical significant difference when survivors
and non-survivors were compared.
Table 5 illustrates the risk factors associated with increased
risk of mortality. In the univariable analysis, the odds of inhospital mortality were higher in advanced age, those suffering
from diabetes mellitus, hypertension or both. Being over
weight and obese, suffering with severe form of illness, requir
ing oxygen supplementation on admission and being admitted
to the ICU and HDU were other factors associated with
increased odds of in-hospital mortality. In the multivariable
logistic regression model, we found advanced age (OR 1.07,

95% CI 1.03–1.11), overweight and obesity (OR 9.44, 95% CI
2.71–41.0), severe form of the disease (OR 4.77, 95% CI
1.18–25.0) and being admitted to the HDU and ICU (OR
6.68, 95% CI 2.06–24.6) to be the primary factors associated
with higher odds of in-hospital mortality.

Discussion
The in-hospital mortality amongst our cohort was 31.8%.
Our study identified several risk factors associated with
mortality amongst hospitalized patients with COVID-19 in
a Tanzanian setting. The in-hospital mortality was lower
compared to the average mortality reported in Africa8 but
higher than the global average amongst hospitalized
patients with COVID-19.23 Our study identified advanced
age, overweight and obesity, severe form of the illness and

Table 5 Factors Associated with Increased Odds of Mortality Among Patients Suffering with COVID-19
Variable

Age (years)

Univariable Analysis

Multivariable Analysis

OR

95% CI

P-value

OR

95% CI

P-value

1.05

1.02–1.08

<0.001

1.07

1.03–1.11

0.001

1.05–4.28

0.037

1.39–5.96

0.004

1.71

0.48–6.24

0.400

Diabetes mellitus
No

Ref

Yes

2.11

Hypertension
No
Yes

Ref
2.87

Diabetes mellitus & hypertension
No

Ref

Yes

4.07

1.84–9.23

<0.001

Ref
0.07

0.02–0.20

<0.001

2.78–22.2

<0.001

9.44

2.71–41.0

0.001

Comorbids
With
Without
BMI
Healthy weight
Overweight & obese

Ref
7.14

Severity
Non severe

Ref

Severe

12.7

4.32–54.7

<0.001

4.77

1.18–25.0

0.039

Ref
9.94

4.68–22.2

<0.001

6.68

2.06–24.6

0.002

21.1

6.09–133.0

<0.001

1.34

1.13–1.59

<0.001

Admitting ward
Isolation ward
CCU (HDU & ICU)
Initial oxygen support
No
Yes
D-dimer > 1 mg/L

Ref
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admission to the CCU (HDU & ICU) as the main factors
associated with higher odds of mortality.
Studies have shown adults are more likely to suffer with
severe form of the disease. The median age of hospitalized
patients with COVID-19 ranges from 49 to 56 years.4,24,25
Our study findings are consistent with reports published
globally and comparable to other studies done in
Africa.8,26 Elderly and males have been found to be at an
increased risk of mortality, this has been associated with the
higher levels of angiotensin-converting enzyme 2 (ACE2),
which is a cell surface receptor for SARS-CoV-2.27
Nevertheless, our study did not find any association
between gender and increased odds of mortality.
Our study also identified obesity to be significantly asso
ciated with in-hospital mortality. Our findings are consistent
with those done in the United States15,28 but contrary to study
findings from ten different countries in Africa.8 We hypothe
size the difference could be in part due to the large cohort of the
foreign community which our center serves. The spectrum of
COVID-19 ranges from mild to critical; however, most indi
viduals suffer from mild form of the disease.9 In our cohort,
more than half of the patients who died were admitted to the
HDU and ICU, suffering from the critical form of illness.
Similar reports of ICU mortality due to COVID-19 have
been reported globally.29–31 It is unfortunate the limited
scope of our study cannot identify the causes of high mortality
in our ICU setting as there is no readily available data.
However globally, acute respiratory distress syndrome
(ARDS),10,12 cardiovascular,16,25,32 thromboembolic33,34 and
neurologic complications35 have been reported as the main
cause of mortality in ICU patients suffering with critical
forms of COVID-19.
Our study results are concordant with reported risk
factors of COVID-19 mortalities worldwide. Our study
had several limitations. This was a single-center obser
vational cohort study in a well-resourced private health
care setting, thus limiting the generalizability of our
results to public facilities. Lack of national guidelines
at the time of the study hindered development, valida
tion and application of appropriate clinical and radiolo
gical scoring systems. Additionally, the retrospective
study design restricted us from following up our patients
after hospital discharge. Despite these limitations, the
experience and the data analyzed have set a benchmark
for more research in addressing areas of clinical
improvement within Tanzania.
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Conclusion
This is the first and the largest study done in Tanzania of
hospitalized COVID-19 patients. This study not only pro
vides a comprehensive assessment of the clinical spectrum
of COVID-19 patients admitted to our specific urban set
ting but also highlights the factors associated with
increased risk of mortality amongst our cohort. We found
that the in-hospital mortality was lower compared to the
average mortality reported in Africa. More importantly,
age, obesity, severe form of the disease and admission to
ICU and HDU were factors strongly associated with
increased risk of mortality.
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